Table 1.
Population baseline characteristics of ALL and AML
| ALL patients, n = 2701 | AML patients, n = 9027 | ||||
|---|---|---|---|---|---|
| Follow‐up, months | Median [IQR] | 99.46 [97.85–101.82] | 98.18 [97.09–99.19] | ||
| Female | n (%) | 1087 (40.3%) | 4373 (48.5%) | ||
| Age at HCT, years | median (min‐max) [IQR] | 34 (18–73.5) [24.3–45.9] | 48.5 (18–77.7) [37.2–57.6] | ||
| KPS | ≥90 | 1592 (77.5%) | 5578 (78.9%) | ||
| Diagnosis | Phineg B ALL | 463 (17.1%) | AML de novo | 7632 (84.5%) | |
| Phipos B ALL | 635 (23.5%) | AML secondary | 1395 (15.5%) | ||
| T ALL | 663 (24.5%) | Cytogenetics favorable | 600 (6.6%) | ||
| Missing | 940 (34.8%) | Cytogenetics intermed | 3091 (34.2%) | ||
| Cytogenetics adverse | 682 (7.6%) | ||||
| Cytogenetics missing | 4654 (51.6%) | ||||
| FLT3 positive | 592 (24.7%) | ||||
| NPM1 positive | 476 (22.3%) | ||||
| Status at transplant | CR1 | 2124 (78.6%) | 6193 (68.6%) | ||
| ≥CR2 | 411 (15.2%) | 1567 (17.4%) | |||
| Advanced | 166 (6.1%) | 1267 (14%) | |||
| MRD pretransplant | Negative | 840 (68.3%) | 1726 (78.9%) | ||
| Positive | 389 (31.7%) | 461 (21.1%) | |||
| missing | 1306 | 5573 | |||
| Type of donor | MSD | 1180 (43.7%) | 4120 (45.6%) | ||
| UD | 1436 (53.2%) | 4472 (49.5%) | |||
| Other relative | 85 (3.1%) | 435 (4.8%) | |||
| Female to male | Yes | 516 (19.3%) | 1523 (17%) | ||
| Cell source | BM | 655 (24.3%) | 1339 (14.8%) | ||
| PB | 2046 (75.7%) | 7688 (85.2%) | |||
| Patient CMV | Positive | 1409 (58.4%) | 5346 (66.1%) | ||
| Donor CMV | Positive | 1167 (48.2%) | 4241 (52.3%) | ||
| ATG | Yes | 1091 (44.3%) | 4387 (53.2%) | ||
| Conditioning | MAC | 2320 (86.5%) | 5151 (57.5%) | ||
| RIC | 361 (13.5%) | 3806 (42.5%) | |||
| CT | 630 (23.5%) | 6309 (70.1%) | |||
| BuCy ± Other | 2013 (23.4%) | ||||
| BuFlu ± Other | 2171 (25.2%) | ||||
| Other CT | 1731 (20,1%) | ||||
| TBI | 2054 (76.5%) | 2686 (29.9%) | |||
| HCT‐CI | 0 | 538 (72.5%) | 1558 (62%) | ||
| 1 or 2 | 118 (15.9%) | 537 (21.4%) | |||
| ≥3 | 86 (11.6%) | 416 (16.6%) | |||
| Acute GVHD < 2 y | Yes | 837 (32.3%) | 2103 (24%) | ||
| Grade I | 577 | 1930 | |||
| Grade II | 616 | 1598 | |||
| Grade III | 183 | 424 | |||
| Grade IV | 38 | 81 | |||
| No aGvHD present | 1175 | 4727 | |||
| missing | 112 | 267 | |||
| Chronic GVHD < 2 y | Yes | 1335 (52.2%) | 4531 (52.5%) | ||
| GVHD prevention | CSA | 221 (9%) | 1200 (14.6%) | ||
| CSA + MTX | 1665 (67.8%) | 4015 (48.8%) | |||
| CSA + MMF | 288 (11.7%) | 1911 (23.2%) | |||
| Other | 282 (11,7%) | 1098 (13,4%) | |||
| PTCy | 126 (1.5%) | ||||
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; BM, bone marrow; BuCy, busulfan cyclophosphamide; BuFlu, busulfan fludarabine; CMV, Cytomegalovirus; CR, complete remission; CR1, 1st Complete Remission; CR2, 2nd Complete Remission; CR3, 3rd Complete Remission; CSA, cyclosporine A; CT, chemotherapy; Cytogenetics, Risk According to MRC Classification (Blood 2010;116:354–65); cGRFS, composite graft‐versus‐host disease‐free, relapse‐free survival; GVHD, graft‐versus‐host disease; HCT, hematopoietic cell transplantation; HCT‐CI, HCT‐Specific Comorbidity Index; HR, hazard ratio; IQR, interquartile range; Intermed, intermediate; KPS, Karnofsky Performance Status; LFS, leukemia‐free survival; MAC, myeloablative conditioning; min, minimum; max, maximum; MMF, mycophenolate mofetil; MSD, matched sibling donor; MTX, methotrexate; NA, not available; NRM, non‐relapse mortality; OS, overall survival; Phineg, Philadelphia chromosome negative; Phipos, Philadelphia chromosome positive; Ref, reference; RI, relapse incidence; TBI, total body irradiation; TCD, T cell depletion; UD, unrelated donor, y, year.